Insulet (PODD) Cash & Equivalents (2010 - 2026)

Insulet (PODD) has reported Cash & Equivalents for 17 consecutive years, with $534.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 52.31% year-over-year to $534.9 million; the trailing twelve-month figure through Jun 2026 stood at $534.9 million (down 52.31% YoY), and the FY2025 full-year result was $716.1 million, down 24.89% from the prior year.
• Cash & Equivalents improved to $534.9 million in Q2 2026 per PODD's latest filing, from $480.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q1 2025 and bottomed at $480.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $767.1 million across 5 years, with a median of $712.8 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 70.81% in 2025, then slumped 62.56% in 2026.
• Over 5 years, Cash & Equivalents stood at $674.7 million in 2022, then advanced by 4.37% to $704.2 million in 2023, then soared by 35.39% to $953.4 million in 2024, then declined by 24.89% to $716.1 million in 2025, then declined by 25.3% to $534.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $534.9 million, $480.4 million, and $716.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.